Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis
The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) and the Israeli Isotopia Molecular Imaging Ltd. (Isotopia) will in future work more closely together in the early detection of prostate cancer and to this end recently concluded an agreement on the joint development and approval of diagnostic reagents. As part of the agreement, the production of these substances shall soon be fully automated through the use of synthesis systems.
Eckert & Ziegler has long been developing and marketing so-called synthesis modules, which are used to prepare short-lived diagnostic reagents in hospitals for tumor diagnosis. So far, one important application field is the production of diagnostics for neuroendocrine tumors (NETs) on the basis of Gallium-68. The new strategic collaboration is intended to ensure that the synthesis modules also will be able to use Isotopia´s simplified method to produce Gallium-68 based diagnostic reagents for the detection of prostate carcinomas in the future.
“Our synthesis modules simplify the work of physicians and medical physicists, so any expansion of the field of application makes sense,” said Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH and responsible for the Lab Devices division. “We hope that this step will not only lead to higher sales of synthesis modules in the medium term, but also to a competitive advantage for our gallium generators, which are compatible to the devices.
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, email@example.com
Note: This press release has been copied from www.ezag.com